# PDUFA dates March 2028: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2028-03

> 38 FDA catalysts are dated in March 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in March 2028

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 2028 | [Sarilumab sar153191 (regn88) primary completion](https://sec-api.dev/pdufa/sarilumab-sar153191-regn88) | SNY | Juvenile Idiopathic Arthritis | scheduled | "NCT02991469 (A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02991469)) |
| March 2028 | [Lifileucel plus pembrolizumab primary completion](https://sec-api.dev/pdufa/lifileucel-plus-pembrolizumab) | IOVA | Metastatic Melanoma; Unresectable Melanoma; Melanoma | scheduled | "NCT05727904 (Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05727904)) |
| March 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07520162 (A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07520162)) |
| March 2028 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07586202)) |
| March 2028 | [TZIELD® (teplizumab) primary completion](https://sec-api.dev/pdufa/teplizumab) | SNY | Type 1 Diabetes Mellitus | scheduled | "NCT06791291 (Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-06 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06791291)) |
| March 2028 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG | scheduled | "NCT07284420 (ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284420)) |
| March 2028 | [PF-08046054 primary completion](https://sec-api.dev/pdufa/pf-08046054) | PFE |  | scheduled | "NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07144280)) |
| March 2028 | [Tilrekimig primary completion](https://sec-api.dev/pdufa/tilrekimig) | PFE | Atopic Dermatitis | scheduled | "NCT07765888 (A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-10 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765888)) |
| March 2028 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Breast Neoplasms | scheduled | "NCT06926868 (A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06926868)) |
| March 2028 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Locally Advanced Cervical Cancer | scheduled | "NCT06943833 (A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943833)) |
| March 2028 | [Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) primary completion](https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con) | SNY | Meningococcal Infection; Healthy Volunteers | scheduled | "NCT07710872 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07710872)) |
| March 2028 | [Berobenatide primary completion](https://sec-api.dev/pdufa/berobenatide) | PFE | Obesity; Overweight | scheduled | "NCT07792954 (A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07792954)) |
| March 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY | Early-Stage Non-Small Cell Lung Cancer | scheduled | "NCT07871214 (A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871214)) |
| March 2028 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Immune Thrombocytopenic Purpura (ITP) | scheduled | "NCT06722235 (A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06722235)) |
| March 2028 | [NBIP-01435 primary completion](https://sec-api.dev/pdufa/nbip-01435) | NBIX | Congenital Adrenal Hyperplasia | scheduled | "NCT07850739 (Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-16 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850739)) |
| March 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873945)) |
| March 2028 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Active Juvenile Psoriatic Arthritis | scheduled | "NCT04804553 (Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04804553)) |
| March 2028 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350097)) |
| March 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Homozygous | scheduled | "NCT06597006 (Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597006)) |
| March 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Heterozygous | scheduled | "NCT06597019 (Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597019)) |
| March 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949684)) |
| March 2028 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Multiple Sclerosis | scheduled | "NCT06141486 (Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06141486)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221188)) |
| March 2028 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE |  | scheduled | "NCT07476287 (Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07476287)) |
| March 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213973)) |
| March 2028 | [Ribupatide primary completion](https://sec-api.dev/pdufa/ribupatide) | KLRA | Obesity With Diabetes; Overweight With Diabetes | scheduled | "NCT07284901 (Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-27 (ESTIMATED); Lead Sponsor Kailera." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284901)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221227)) |
| March 2028 | [Ordspono™ (odronextamab) primary completion](https://sec-api.dev/pdufa/odronextamab) | REGN | Diffuse Large B-cell Lymphoma (DLBCL) | scheduled | "NCT06091865 (A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06091865)) |
| March 2028 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Crohn's Disease | scheduled | "NCT07403968 (A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07403968)) |
| March 2028 | [Active oral hygiene regimen primary completion](https://sec-api.dev/pdufa/active-oral-hygiene-regimen) | CL | Periodontal Disease; Gingival Inflammation and Bleeding | scheduled | "NCT07803484 (Efficacy of Oral Hygiene Regimens in Patients Undergoing Non-Surgical Periodontal Treatment): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-03-30 (ESTIMATED); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07803484)) |
| March 31, 2028 | [ALXN1840 NDA/BLA submission](https://sec-api.dev/pdufa/alxn1840) | MNPR |  | scheduled | "Examples of these forward-looking statements include statements concerning the following: that Dr. Kent is leading the Company's medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that the Company is on track to complete the NDA submission within the next several weeks; and that Monopar expects its current funds to support operations through at least March 31, 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926036385/ex_1043550.htm)) |
| March 2028 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT03998254 (Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998254)) |
| March 2028 | [Olpasiran primary completion](https://sec-api.dev/pdufa/olpasiran) | AMGN | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581303)) |
| March 2028 | [Pembrolizumab (+) berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa) | MRK | Squamous Cell Carcinoma | scheduled | "NCT06041802 (A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06041802)) |
| March 2028 | [AMVUTTRA® (vutrisiran) primary completion](https://sec-api.dev/pdufa/vutrisiran) | ALNY | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | scheduled | "NCT06679946 (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679946)) |
| March 2028 | [FG-3246 primary completion](https://sec-api.dev/pdufa/fg-3246) | KYNB | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06842498 (A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842498)) |
| March 2028 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer ( SCLC ) | scheduled | "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465757)) |
| March 2028 | [Bgb-b2033 primary completion](https://sec-api.dev/pdufa/bgb-b2033) | ONC | Hepatocellular Cancer; Liver Cancer; Hepatocellular Carcinoma | scheduled | "NCT07911683 (Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911683)) |

Other months: https://sec-api.dev/fda-calendar/2028-02 , https://sec-api.dev/fda-calendar/2028-04. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates March 2028: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2028-03

```bibtex
@misc{secapidev_fda_calendar_2028_03_20261116,
  title        = {PDUFA dates March 2028: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2028-03}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2028_03_20261116","title":"PDUFA dates March 2028: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2028-03","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
